Tagged with generic

Turkey Tahsin Yüksel, general manager of Teva Turkey, analyzes the strategic importance of pharmaceutical branding in Turkey, shares the story of Teva’s adaptation to the unique market needs, and offers his insight of what can be expected of the industry in the wake of the country’s current economic hardships.   It…

Malaysia Fabio Sperandei has been the country head for Sandoz Malaysia for four years. Here, he explains the key success factors that led Sandoz to become the leading multinational generic company in Malaysia as well as the importance of a manager working closely with his team to achieve growth.   Malaysia…

France Catherine Bourrienne-Bautista, Déléguée générale of the GEMME (L’association Genérique Même Medicament, France’s generics and biosimilars association), provides her take on the state of the generics and biosimilars industry in France. Bourrienne-Bautista offers her thoughts on the 8th edition of the Strategic Council of Health Industries (CSIS) and outlines a plan…

Malaysia Ch’ng Kien Peng, executive director of Xepa-Soul Pattinson, offers insights on the dynamic healthcare industry in Malaysia and the new government’s key role in supporting the local industry. He also details Xepa-Soul Pattinson’s strong footprint in the country as well as the company’s geographic expansion plans outside of Malaysia.  …

Malaysia Indranil Sen, managing director of Ranbaxy Malaysia, a Sun Pharma company, discusses the role of generics in the Malaysian pharmaceutical sector, and their strategy to lead the market, rather than becoming a “me too” generics company.   What have been your main goals that you have set out to achieve…

Europe European countries ranked by the levels of generics penetration within their domestic markets. Poland comes out on top by this measurement, with generic medicines making up a full 60.4% of market sales value, followed closely by Russia and Italy. At the other end of the scale, generics make up just…

Algeria With non WTO members such as Algeria flouting intellectual property (IP) it raises the issue of how best to protect and price medicines in the future. In a fascinating interview we spoke to Rachid Kerrar from the Algerian firm Beker about their development of a cheaper, generic version of Gilead’s…

Algeria Hepatitis C generics brought Beker to fame, but today its director general Rachid Kerrar discloses the new paths the company is exploring, such as new formulations and an increased focus on exports. He also praises the opportunities for business in pharmaceuticals in Algeria.   Rachid, Beker is most famous for…

Algeria Essam Farouk, President of MS Pharma provides insights on the success of its local manufacturing operations in Algeria, and the country’s potential to become an export hub. What recent changes have taken place within the MS Pharma group? We are planning expansions both inside and outside the Middle East and…

Algeria Sofiane Achi of El Kendi, one of Algeria’s leading pharma manufacturers, discusses the fresh ideas he has brought back to the company following a stint at Boehringer Ingelheim, manufacturing upgrades, and the country’s readiness for biosimilars. You decided to return to a company that you already know very well. How…

UK Thomas Broeer, managing director UK and Ireland for Aurobindo, has been at the helm of Aurobindo’s UK subsidiary, Milpharm Limited for almost two years and here discusses the UK market’s strengths, the potential impact of Brexit on the pharmaceutical industry and the pricing structures in place in the UK.  …

UK Thembalath Ramachandran, chairman and managing director of one of the UK’s fastest growing generics manufacturers, Bristol Laboratories, describes why he chose to relocate from India to start his business, the company’s significant manufacturing footprint in the UK, and how the British government could be doing more to support homegrown manufacturers.…